Benjamin A Bradley

Title: The Innovations of Benjamin A. Bradley

Introduction

Benjamin A. Bradley is a notable inventor based in Winterbourne Down, GB. He is recognized for his significant contributions to the field of immunology, particularly in the development of human monoclonal antibodies. His work has implications for blood typing and the prevention of hemolytic disease in newborns.

Latest Patents

Bradley's most recent patent focuses on "Human anti-RH(D) monoclonal antibodies reagents and hybridomas." This invention provides human monoclonal antibodies with essential characteristics, including binding to the Rh(D) antigen while not interacting with other Rh blood group antigens. The antibodies are IgGl proteins with kappa light chains and specific allotypes. They are designed to bind to D.sup.u cells through an indirect antiglobulin test and to various D variant antigens, while avoiding binding to certain other variants. This innovation is crucial for Rh-typing of red blood cells and offers a method for passive immunization to prevent hemolytic disease of the newborn. The monoclonal antibodies are exemplified by cell lines ECACC 87091605 and 87091604, which were deposited in 1987.

Career Highlights

Bradley is affiliated with the National Blood Authority, where he applies his expertise in immunology and antibody development. His work has been instrumental in advancing the understanding and application of monoclonal antibodies in clinical settings.

Collaborations

Bradley has collaborated with notable colleagues, including Alan Doyle and Belinda Mary Kumpel, contributing to the advancement of research in his field.

Conclusion

Benjamin A. Bradley's innovative work in the development of human monoclonal antibodies has made a significant impact on immunology and blood transfusion practices. His contributions continue to influence the medical field and improve patient outcomes.